| Verum (n = 29) x ± SD | Placebo (n = 25) x ± SD | ||||
---|---|---|---|---|---|---|
Baseline | Week 6 | Diff | Baseline | Week 6 | Diff | |
LA (mm) | 35.8 ± 5.9 | 37.1 ± 5.0 | 1.39 ± 2.92# | 36.4 ± 6.4 | 35.8 ± 6.1 | − 0.68 ± 4.26 |
RVEDD (mm) | 26.8 ± 5.3 | 26.3 ± 3.4 | − 0.52 ± 4.67 | 25.2 ± 4.1 | 25.1 ± 3.5 | − 0.08 ± 4.29 |
LVEDD (mm) | 49.0 ± 5.7 | 47.6 ± 7.1 | − 1.34 ± 5.47# | 47.9 ± 6.9 | 48.4 ± 7.5 | 0.52 ± 5.64 |
LVESD (mm) | 30.4 ± 4.9 | 30.1 ± 5.5 | − 0.31 ± 3.27 | 29.5 ± 5.2 | 30.2 ± 6.7 | 0.72 ± 4.20 |
LVEF (%) | 68.6 ± 8.3 | 70.2 ± 9.0 | 1.66 ± 8.94 | 70.0 ± 9.3 | 70.3 ± 8.9 | 0.28 ± 10.81 |
  < 65% (n/%) | 10 (34.5%) | 9 (31.0%) | – | 6 (24.0%) | 7 (28.0%) | – |
  < 65% | 59.5 ± 4.2 | 66.8 ± 9.5 | 7.30 ± 8.22# | 57.5 ± 5.4 | 64.5 ± 11.8 | 7.00 ± 7.75 |
  ≥ 65% | 73.5 ± 5.5 | 72.5 ± 8.4 | − 1.00 ± 8.07 | 74.0 ± 6.3 | 72.1 ± 7.3 | − 1.84 ± 10.93 |
IVS (mm) | 10.6 ± 1.6 | 9.9 ± 1.9 | − 0.62 ± 1.78 | 10.6 ± 1.4 | 10.2 ± 1.5 | − 0.44 ± 1.32 |
LVPW (mm) | 10.7 ± 1.6 | 10.3 ± 1.6 | − 0.41 ± 1.52 | 10.4 ± 1.5 | 10.2 ± 1.6 | − 0.20 ± 1.12 |
E/E´ > 8 (n/%) | 2 (25.0%) | 3 (37.5%) | – | 2 (33.3%) | 0 (0.0%) | – |
E wave | 0.73 ± 0.19 | 0.71 ± 0.16 | − 0.02 ± 0.18 | 0.73 ± 0.18 | 0.72 ± 0.15 | − 0.01 ± 0.15 |
A wave | 0.74 ± 0.24 | 0.68 ± 0.28 | − 0.06 ± 0.19 | 0.71 ± 0.18 | 0.73 ± 0.15 | 0.01 ± 0.16 |
E/A ratio | 1.05 ± 0.35 | 1.18 ± 0.49 | 0.13 ± 0.38# | 1.45 ± 2.04 | 1.02 ± 0.21 | − 0.42 ± 2.04 |
LVMI g/m2 | 98.2 ± 24.4 | 90.0 ± 37.0 | −8.15 ± 35.48## | 93.5 ± 26.5 | 90.9 ± 25.9 | −2.61 ± 21.20 |
LVMI g/m2 femalea | 87.2 ± 16.6 | 77.7 ± 20.9 | −9.5 ± 15.6# | 89.0 ± 26.2 | 80.2 ± 21.8 | −8.7 ± 23.1 |
LVMI g/m2 maleb | 108.4 ± 26.4 | 101.5 ± 45.1 | −6.9 ± 47# | 98.4 ± 27.1 | 102.4 ± 25.9 | 4.0 ± 17.5 |